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In a seminal New England Journal of Medicine article, pub-
lished 40 years ago, Folkman proposed the concept that
angiogenesis could be a target for cancer therapy [1]. This
proposal emerged from early observations that some tumors
cells were capable of stimulating endothelial cells to form
new capillary sprouts and that nonvascularized tumors were
held in a dormant state, unable to grow beyond a size larger
than 2-3mm3. These and related observations led Folkman
to cautiously conclude that “...the mechanism by which
tumor implants stimulate neovascularization must be well
understood before therapy based upon interference with
angiogenesis can be devised.” Since then, a wide variety of
antiangiogenic therapies have been tested in clinical trails,
with relatively modest improvements in patient outcomes
and unforeseen therapeutic challenges. These initial setbacks
call for a reinvigorated research eﬀort to better understand
the complex molecular and biological relations between
tumor cells and endothelial cells within a neoplasm and
the development of new, more eﬀective, therapeutic tools
targeting tumor angiogenesis. Encouraging this research is
the theme of this special issue of the Journal of Oncology.
Folkman’s original proposal to target angiogenesis for
cancer therapy relied on several assumptions. One key
assumption was that solid tumors would only grow beyond
as i z eo f2 - 3 m m 3 after vascularization was established,
leading to more eﬃcient diﬀusion of oxygen, nutrients, and
wastes. A second assumption was that tumor cells produce
angiogenesis in part by stimulating the growth of endothelial
cells from surrounding vessels. A third assumption was
that blocking angiogenesis would suppress tumor growth
and result in resumption of tumor dormancy. The fourth
assumption was that antiangiogenic cancer therapy could
be delivered chronically because angiogenic activity is of
minimal importance to healthy tissues.
Since Folkman’s landmark paper, several factors have
been recognized as critical for the induction of tumor
angiogenesis, with one of these being vascular endothelial
growth factor (VEGF) and its interaction with VEGF
receptors. Many therapeutic strategies were developed to
either block VEGF, block VEGF binding to its receptor, or
interfere with intracellular signaling in the VEGF receptor
pathway. Early work in preclinical models led to clinical
studies and the development of a multitude of antibodies
and small molecules that target tumor angiogenesis. Several
clinical trials provided encouraging evidence supporting
the use of these agents in the treatment of breast cancer,
lung cancer, kidney cancer, and colon cancer. However,
resistance to antiangiogenic agents was seen in clinical
trials, challenging the notion that endothelial cells supplying
the tumor vasculature are genetically stable and, therefore,
unlikely to develop mutations that lead to such resistance.
Furthermore,thereareindicationsthattheinitialresponseto
clinicalantiangiogenicagentsmayleadtothedevelopmentof
moreaggressivetumors.Sincethenwehaveidentiﬁedseveral
other pathways involved in the biology of angiogenesis and
also identiﬁed several mechanisms leading to the resistance.
Lymphangiogenesis and lymph node metastases are
another critical determinant of tumor progression and may
even be responsible for the emergence of resistance to cancer
therapy. Yu and colleagues and Kitadai review the literature2 Journal of Oncology
pertaining to lymphangiogenesis in breast and gastric can-
cers, respectively. Though endothelial in origin, lymphatic
endothelial cells are distinct with speciﬁc cell surface recep-
tors. Their origin, proliferation, and survival may pose a
major challenge in treating cancer with angiogenesis-based
therapy. Therefore, therapies targeting lymphangiogenesis,
in addition to angiogenesis, oﬀer promising prospects to
achieve improved cancer management.
This special issue set out to address several issues related
to tumor angiogenesis, such as, the mechanisms by which
tumorcellsacquirethecapabilityto“turnon”theangiogenic
switch, the inﬂuence of the tumor microenvironment on
angiogenesis(Campbelletal.,SchmidtandVarner,Tilanand
Kitlinska, Rigogliuso et al., Oettgen), types of resistance to
antiangiogenic therapy (Grepin and Pages, Rahman et al.),
and the development of novel angiogenic strategies (Colema
et al., Corti et al., Otten, Bokemeyer, and Fiedler, Seyfried
and Mukherjee). Invited papers address several of the above
topics and this issue is divided into the following chapter
subgroups: biology of tumor angiogenesis, discovery of
new angiogenesis targets for cancer therapy, disease-speciﬁc
tumor angiogenesis, and disease-speciﬁc cancer therapies.
There will be several review and research papers addressing
all those issues.
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